A primer on Viking Therapeutics and its VK2735 obesity drug in Phase 3
Viking says patients kept up to 97% of lost weight after cutting VK2735 shots to every two weeks, while cash fell to $502 million as trial costs rose.
Recap by typeshit. Full story at note.